Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MFA 370

Next Previous
X
Search
Drug Profile

MFA 370

Alternative Names: MFA-370

Latest Information Update: 10 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ectin Research AG
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I/II Bladder cancer
  • Preclinical Breast cancer; Colorectal cancer; Triple negative breast cancer; Ureteral neoplasms; Uveal melanoma

Most Recent Events

  • 26 Sep 2024 Ectin Research AB terminates phase I/II MANHATTAN trial prior to enrollment in Bladder cancer (Metastatic disease) in Sweden, Denmark and Lithuania (NCT05390645) (EudraCT-2021-000068-30)
  • 31 Jan 2024 Pharmacodynamics data from a preclinical study in Triple-negative-breast-cancer released by Ectin Research AG
  • 07 Dec 2023 MFA 370 is available for licensing as of 07 Dec 2023. https://www.ectinresearch.com/company/ (Ectin Research website, December 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top